Clinical efficacy of an antibody-based detection system for human papilloma virus infection in oral squamous cell carcinoma.
Biomarker
HPV
Head and neck cancer
Human papilloma virus
Oral cancer
p16 expression
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
18
03
2020
accepted:
17
09
2020
pubmed:
25
10
2020
medline:
24
4
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
There is an increasing number of oral squamous cell carcinoma (OSCC) associated with HPV-16. However, p16 expression by immunohistochemistry as the current gold standard for a surrogate marker for virus infection reveals unsatisfying diagnostic accuracy. The aim of this study was to investigate a new rapid test for L1 antibody detection (Prevocheck®) and to validate its diagnostic performance. In a prospective study, the HPV 16 association of all consecutive patients with an OSCC treated between 2015 and 2019 were analyzed by L1 seropositivity (via PrevoCheck®), p16 immunostaining, and partly multiplex PCR for subtype analysis. Overall (n = 107), p16 expression was positive in 17 cases (15.9%), and L1 antibody seropositivity in 7 cases (6.5%). In PCR analysis, two cases of HPV35 and 50 were found. Total HPV prevalence was 8.4% overall and 6.5% for HPV-16. An inferior diagnostic accuracy for HPV-16-associated OSCC in comparison to PrevoCheck® was revealed. The rapid test for L1 antibodies showed an optimal sensitivity and specificity, positive and negative predictive value, and an overall diagnostic accuracy of 100%. However, HPV prevalence seems low in OSCC. L1 rapid test may represent an additional diagnostic staging method to detect HPV-16 association rather than p16 immunohistochemistry.
Identifiants
pubmed: 33098030
doi: 10.1007/s00784-020-03601-0
pii: 10.1007/s00784-020-03601-0
pmc: PMC8060226
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
Types de publication
Journal Article
Langues
eng
Pagination
2837-2843Subventions
Organisme : Abviris Deutschland GmbH
ID : -
Organisme : Abviris Deutschland GmbH
Références
van Dijk BA et al (2016) Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands. Int J Cancer 139(3):574–583
doi: 10.1002/ijc.30107
Zhang SK, Zheng R, Chen Q, Zhang S, Sun X, Chen W (2015) Oral cancer incidence and mortality in China, 2011. Chin J Cancer Res 27(1):44–51
doi: 10.1007/s11670-008-0044-x
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294–4301
doi: 10.1200/JCO.2011.36.4596
Attner P, du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, Munck-Wikland E (2010) The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 126(12):2879–2884
pubmed: 19856308
Kim SM et al (2017) Identification of human papillomavirus (HPV) subtype in oral cancer patients through microarray technology. Eur Arch Otorhinolaryngol 274:4255–4257
doi: 10.1007/s00405-017-4662-0
Kruger M et al (2014) The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: a retrospective analysis of 88 patients and literature overview. J Craniomaxillofac Surg 42(7):1506–1514
doi: 10.1016/j.jcms.2014.04.022
Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison ML (2013) Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49(1):1–8
doi: 10.1016/j.oraloncology.2012.07.002
Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–420
doi: 10.1093/jnci/djn025
Vlantis AC (2016) Human papilloma virus and oropharyngeal carcinoma - lessons from history. Chin J Dent Res 19(1):9–16
pubmed: 26981602
Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, Robinson M, Powell N (2013) Human papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer 13:220
doi: 10.1186/1471-2407-13-220
Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22(5):1071–1077
doi: 10.1093/annonc/mdr006
O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 17(4):440–451
doi: 10.1016/S1470-2045(15)00560-4
Awan MS, Irfan B, Zahid I, Mirza Y, Ali SA (2017) Comparison of polymerase chain reaction and immunohistochemistry assays for analysing human papillomavirus infection in oral squamous cell carcinoma. J Clin Diagn Res 11(6):XC10–XC13
pubmed: 28764278
pmcid: 5535468
Holzinger D, Wichmann G, Baboci L, Michel A, Höfler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T (2017) Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer 140(12):2748–2757
doi: 10.1002/ijc.30697
Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O'Sullivan B, Waldron J, Cummings B, Kim J, Ringash J, Dawson LA, Gullane P, Siu L, Gillison M, Liu FF (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27(36):6213–6221
doi: 10.1200/JCO.2009.23.1670
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, le QT (2014) p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32(35):3930–3938
doi: 10.1200/JCO.2013.54.5228
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122–137
doi: 10.3322/caac.21389
Albers AE, Qian X, Kaufmann AM, Coordes A (2017) Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci Rep 7(1):16715
doi: 10.1038/s41598-017-16918-w
Smitha T, Mohan CV, Hemavathy S (2017) Prevalence of human papillomavirus16 DNA and p16INK4a protein in oral squamous cell carcinoma: a systematic review and meta-analysis. J Oral Maxillofac Pathol 21(1):76–81
doi: 10.4103/jomfp.JOMFP_248_16
Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjønneland A, Overvad K, Quirós JR, González CA, Sánchez MJ, Larrañaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PHM, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, Ekström J, Skeie G, Lund E, Weiderpass E, Ferrari P, Byrnes G, Romieu I, Riboli E, Hildesheim A, Boeing H, Pawlita M, Brennan P (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31(21):2708–2715
doi: 10.1200/JCO.2012.47.2738
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35
doi: 10.1056/NEJMoa0912217
Weichert W et al (2017) S1-Leitlinie zur pathologisch-anatomischen Diagnostik von Plattenepithelkarzinomen des Kopf-Hals-Bereiches. Bundesverband der Deutschen Pathologen und Deutsche Gesellschaft für Pathologie.
Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, Waterboer T (2006) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44(2):504–512
doi: 10.1128/JCM.44.2.504-512.2006
Deschuymer S, Dok R, Laenen A, Hauben E, Nuyts S (2018) Patient selection in human papillomavirus related oropharyngeal cancer: the added value of prognostic models in the new TNM 8th edition era. Front Oncol 8:273
doi: 10.3389/fonc.2018.00273
Yang H et al (2018) The role of protein p16(INK4a) in non-oropharyngeal head and neck squamous cell carcinoma in Southern China. Oncol Lett 16(5):6147–6155
pubmed: 30333880
pmcid: 6176411
Sun Y, Zhang Y, Liu L, Song X, Li G (2015) Genetic polymorphisms and HPV infection in oral squamous cell carcinomas. Curr Opin Virol 14:1–6
doi: 10.1016/j.coviro.2015.05.004
Belobrov S, Cornall AM, Young RJ, Koo K, Angel C, Wiesenfeld D, Rischin D, Garland SM, McCullough M (2018) The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med 47(1):18–24
doi: 10.1111/jop.12649
El-Bayoumy K et al (2020) An integrated approach for preventing oral cavity and oropharyngeal cancers: two etiologies with distinct and shared mechanisms of carcinogenesis. Cancer Prev Res (Phila) 13(8):649–660
doi: 10.1158/1940-6207.CAPR-20-0096
Zafereo ME, Xu L, Dahlstrom KR, Viamonte CA, el-Naggar AK, Wei Q, Li G, Sturgis EM (2016) Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. Oral Oncol 56:47–53
doi: 10.1016/j.oraloncology.2016.03.003
D’Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C (2017) Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and HPV detection method. JAMA Oncol 3(2):169–177
doi: 10.1001/jamaoncol.2016.3067
Sgaramella N, Coates PJ, Strindlund K, Loljung L, Colella G, Laurell G, Rossiello R, Muzio LL, Loizou C, Tartaro G, Olofsson K, Danielsson K, Fåhraeus R, Nylander K (2015) Expression of p16 in squamous cell carcinoma of the mobile tongue is independent of HPV infection despite presence of the HPV-receptor syndecan-1. Br J Cancer 113(2):321–326
doi: 10.1038/bjc.2015.207
Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, Bosch FX, de Sanjosé S, Trottier H (2014) HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 15(12):1319–1331
doi: 10.1016/S1470-2045(14)70471-1
Hoffmann M, Tribius S (2019) HPV and oropharyngeal cancer in the eighth edition of the TNM classification: pitfalls in practice. Transl Oncol 12(8):1108–1112
doi: 10.1016/j.tranon.2019.05.009
Schroeder L, Wichmann G, Willner M, Michel A, Wiesenfarth M, Flechtenmacher C, Gradistanac T, Pawlita M, Dietz A, Waterboer T, Holzinger D (2017) Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. Int J Cancer 142(7):1361–1368. https://doi.org/10.1002/ijc.31167
doi: 10.1002/ijc.31167
pubmed: 29159804
Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsague X, Macfarlane TV, Biggs AM, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P (2013) Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst 105(8):536–545
doi: 10.1093/jnci/djt053
Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T (2016) Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol 42:46–52
doi: 10.1016/j.canep.2016.03.003
Zhang Y, Waterboer T, Haddad RI, Miles BA, Wentz A, Gross ND, Fakhry C, Quon H, Lorch JH, Gourin CG, Clayburgh D, Misiukiewicz KJ, Richmon JD, Andersen PE, Posner MR, D'Souza G (2017) Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncol 67:77–82
doi: 10.1016/j.oraloncology.2017.02.004
Doorbar J (2007) Papillomavirus life cycle organization and biomarker selection. Dis Markers 23(4):297–313
doi: 10.1155/2007/613150
Wentzensen N (2011) Molecular diagnosis of HPV infections. Pathologe 32(6):461–466
doi: 10.1007/s00292-011-1475-6
Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH (2010) Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34(8):1077–1087
doi: 10.1097/PAS.0b013e3181e8b2c4
Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, Locati L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A (2017) In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. Hum Pathol 74:32–42. https://doi.org/10.1016/j.humpath.2017.09.011
doi: 10.1016/j.humpath.2017.09.011
pubmed: 28993274